 |
Top 22 Urology startups
Oct 10, 2024 | By Jason Kwon | 16 |
These startups develop new urological condition treatments and diagnostics technologies, like robotic-assisted surgery, multiparametric magnetic resonance imaging, endoscopic ultrasound, wearable urinary monitoring devices, artificial intelligence for diagnostic imaging, laser-based therapies
1
Country: France | Funding: €81M
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
UroMems ambition is to offer to the patients suffering from severe urinary incontinence a simple and efficient innovative solution. UroMems is currently developing an active implantable medical device which compensates for sphincter insufficiency.
2
Country: USA | Funding: $624M
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
Tricida is working to turn the tide on Metabolic Acidosis and progression of Chronic Kidney Disease. Its lead product candidate, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease (CKD).
3
Country: Poland | Funding: $377.4M
DEBN is a medical device company developing a novel prostate biopsy needle for urologists which reduces infectious complication rate by delivering the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start.This augmented prophylaxis could save $2B cost of infections' treatment following 5M biopsies worldwide.
DEBN is a medical device company developing a novel prostate biopsy needle for urologists which reduces infectious complication rate by delivering the optimal antibiotic combination directly to the prostate, precisely at the place where potential infections start.This augmented prophylaxis could save $2B cost of infections' treatment following 5M biopsies worldwide.
4
Country: USA | Funding: $237.5M
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
Escient Pharmaceuticals is a provider of bio-technical research and development services intended to focus in advancement of first-in-class G Protein-Coupled Receptor targeted drugs. The company's services focuses on offering therapies for neuro-immuno-inflammatory and autoreactive diseases
5
Country: USA | Funding: $210M
Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.
Goldfinch is singularly focused on discovering and developing precision therapies for patients with kidney disease.
6
Country: USA | Funding: $198.8M
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
Allena Pharmaceuticals is dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic disorders that affect the kidney. The company is focused on metabolic disorders that result in excess accumulation of certain metabolites, such as oxalate and urate, that can cause kidney stones, damage the kidney, and potentially lead to chronic kidney disease, or CKD, and end-stage renal disease.
7
Country: Israel | Funding: $185M
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
Healthy.io de Dip.io, a home-based urinalysis kit that turns a smartphone into a clinical-grade diagnostic device. It’s the first smartphone-based urine test to secure clearance as a Class 2 device.
8
Country: UK | Funding: $106.7M
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
RenalytixAI is a developer of artificial intelligence (AI) enabled clinical diagnostic solutions for kidney disease.
9
Country: USA | Funding: $97.2M
Kalera Medical is the developer of a kidney stone retrieval device designed to remove kidney stone fragments. The company's device is vacuum-assisted that helps in extracting stones from a patient's kidney, enabling doctors to remove stone fragments completely, thereby addressing unmet medical needs.
Kalera Medical is the developer of a kidney stone retrieval device designed to remove kidney stone fragments. The company's device is vacuum-assisted that helps in extracting stones from a patient's kidney, enabling doctors to remove stone fragments completely, thereby addressing unmet medical needs.
10
Country: Sweden | Funding: $87.6M
OxThera is developing its Oxabact therapy that uses the O. formigenes bacteria to degrade oxalates in the intestines.
OxThera is developing its Oxabact therapy that uses the O. formigenes bacteria to degrade oxalates in the intestines.
